The Eastern European market presents tremendous opportunities for healthcare and life sciences companies. But despite reform efforts, corruption continues to permeate the healthcare sectors of Eastern European countries, and a failure to address and mitigate sector-specific corruption risks can lead to enforcement action under local law or anti-corruption laws having extraterritorial effect. In this guest article, Ropes & Gray partner Amanda Raad and associates Stephanie Busalacchi and Andris Ivanovs discuss the key sector-specific risks facing healthcare companies operating or seeking to operate in the region and outline mitigation steps companies should consider. See “Canadian Health Science Company and Employee Settle Civil FCPA Charges in Failed Quest for Drug Distribution in Russia” (Mar. 9, 2016).